ATN-161
Also known as: Ac-PHSCN-NH2, ATN-161, ATN161, PHSCN
Source ATN-161 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
ATN-161 (Ac-PHSCN‑NH2) is a 5‑amino‑acid synthetic peptide that antagonizes integrin α5β1. It has been evaluated in pre‑clinical and early‑phase clinical studies for anti‑angiogenic, anti‑tumor, anti‑viral (e.g., SARS‑CoV‑2), and anti‑fibrotic applications, but it has not received regulatory approval.
Mechanism of Action
Binds the extracellular domain of integrin α5β1, blocking fibronectin interaction and downstream signaling that drives angiogenesis, tumor cell adhesion, and inflammation.
Routes of Administration
Goals & Uses
- COVID‑19 antiviral adjunctInfectious DiseaseLow
- Fibrosis mitigationFibrotic DiseaseLow
- Glioblastoma treatmentNeuro OncologyLow
- Metastasis inhibitionOncologyModerate
- Tumor growth inhibitionOncologyModerate
- Anti-angiogenesisOncology / VascularModerate
- Anti‑angiogenesisVascularModerate
- Combination chemotherapy sensitizationOncologyLow
- Antitumor activity in solid tumorsOncologyModerate
Contraindications
- Hypersensitivity to ATN-161 or fibronectin-derived peptidesAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to ATN-161 or its excipientsAllergyHigh
- Active bleeding disordersHematologyModerate
Adverse Effects
- ThrombocytopeniaHematologicUncommonLow platelet count
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Infusion‑related reaction (flushing, rash)GeneralCommon
- Elevated liver enzymesHepaticRareIncrease in AST/ALT or other hepatic markers
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- CarboplatinLow
- Anticoagulants / antiplatelet agentsModerate
- Anticoagulants (e.g., warfarin, heparin)Moderate
- TemozolomideLow
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- European UnionResearchNo marketing authorization; used in academic studies.
- United StatesInvestigationalIND filed; Phase I/II trials ongoing.
- United KingdomInvestigationalClinical trial approval under MHRA.
Investigational New Drug (IND) status in the United States; no marketing authorization in EU or UK.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is ATN-161?
ATN-161 (Ac-PHSCN‑NH2) is a 5‑amino‑acid synthetic peptide that antagonizes integrin α5β1. It has been evaluated in pre‑clinical and early‑phase clinical studies for anti‑angiogenic, anti‑tumor, anti‑viral (e.g., SARS‑CoV‑2), and anti‑fibrotic applications, but it has not received regulatory approval.
What is ATN-161 used for?
ATN-161 is educationally associated with: COVID‑19 antiviral adjunct, Fibrosis mitigation, Glioblastoma treatment, Metastasis inhibition, Tumor growth inhibition, Anti-angiogenesis, Anti‑angiogenesis, Combination chemotherapy sensitization, Antitumor activity in solid tumors. Educational only — not medical advice.
How is ATN-161 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of ATN-161?
Reported adverse effects include: Thrombocytopenia, Headache, Nausea, Fatigue, Infusion‑related reaction (flushing, rash), Elevated liver enzymes, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid ATN-161?
Recorded contraindications: Hypersensitivity to ATN-161 or fibronectin-derived peptides, Pregnancy, Known hypersensitivity to ATN-161 or its excipients, Active bleeding disorders. Consult a qualified clinician before use.